---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-24-000097"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:09:23.800536+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pacira Q2 2024: Revenue $178M, GAAP EPS $0.39; CMS proposes EXPAREL outpatient reimbursement under NOPAIN

## Summary
- Total revenues of $178.0M, up 5% YoY; EXPAREL sales $136.9M (+1.3%), ZILRETTA $30.7M.
- GAAP net income $18.9M ($0.39 diluted EPS) vs $25.8M ($0.51) in Q2 2023.
- Non-GAAP net income $44.2M ($0.89 diluted EPS) vs $36.0M ($0.71) a year ago; adjusted EBITDA $62.1M.
- CMS proposed rule would separately reimburse EXPAREL in HOPD/ASC starting Jan 2025 under NOPAIN Act.
- Full-year 2024 revenue guidance reiterated at $680M-$705M; $150M share repurchase program ongoing.

## SEC filing metadata
- accession: 0001396814-24-000097
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000097/0001396814-24-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000097/pcrx-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-24-000097
- JSON: https://secwatch.observer/filing/0001396814-24-000097.json
- Plain text: https://secwatch.observer/filing/0001396814-24-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.